Healthcare markets for dementia and oncology trials projected to grow through 2030

The global dementia treatment market is projected to reach $31.13 billion by 2030, growing from an estimated $19.95 billion in 2025. This growth is driven by an aging global population, rising Alzheimer's prevalence, and advancements in precision medicine and disease-modifying therapies. Key treatment categories include antipsychotics, cholinesterase inhibitors, and memantine. Technological integration is also expanding, such as Otsuka Pharmaceutical’s partnership with Jollygood to launch VR training for caregivers, and Ripple’s acquisition of Kinto to incorporate AI into dementia care platforms.

Simultaneously, the oncology clinical trials market is expected to grow to $20.4 billion by 2030, with a compound annual growth rate of 6.3%. This expansion is fueled by rising cancer incidence rates, increased R&D investment from biotech firms, and the integration of AI and big data into trial designs. The Asia-Pacific region is emerging as the fastest-growing market. Trends in this sector include the development of personalized oncology treatments, the use of digital patient monitoring tools, and an increase in multi-center global trials.